FluoSphera develops Liquid Microphysiological Systems to better predict the efficacy and safety of candidate drugs with an unprecedented multiplexing capacity. Our LMSs allow pharmaceutical companies to de-risk their drug discovery pipelines much earlier, thus decreasing their costs of failure.